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Venezuelan equine encephalitis virus replicon particles (VRP) were engineered to express different forms of SIV Gag to compare expression in
vitro, formation of intra- and extracellular structures and induction of humoral and cellular immunity in mice. The three forms examined were full-
length myristylated SIV Gag (Gagmyr+), full-length Gag lacking the myristylation signal (Gagmyr−) or a truncated form of Gagmyr− comprising
only the matrix and capsid domains (MA/CA). Comparison of VRP-infected primary mouse embryo fibroblasts, mouse L929 cells and primate
Vero cells showed comparable expression levels for each protein, as well as extracellular virus-like particles (VRP-Gagmyr+) and distinctive
cytoplasmic aggregates (VRP-Gagmyr−) with each cell type. VRP were used to immunize BALB/c mice, and immune responses were compared
using an interferon (IFN)-γ ELISPOT assay and a serum antibody ELISA. Although all three VRP generated similar levels of IFN-γ-producing
cells at 1 week post-boost, at 10 weeks post-boost the MA/CA-VRP-induced response was maintained at a significantly higher level relative to
that induced by Gagmyr+-VRP. Antibody responses to MA/CA-VRP and Gagmyr+-VRP were not significantly different.
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nodeficiency virus type 1 (HIV-1) remains a critical need,
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doi:10.1016/j.virol.2006.12.029technologies, namely genetic vaccines, which combine the
safety of a subunit vaccine with the ability to present
endogenously produced proteins to the immune system, an
advantage previously only associated with live virus vaccines.
Vaccine vectors based on purified DNA, live viruses or
defective viruses differ in properties that may have a direct
impact on their ability to induce protective immunity to HIV-1,
such as the cells that are targeted, the amount of immunogen
that is synthesized and persistence of the vector in the host
(Amara and Robinson, 2002; Barouch et al., 2001; Schnell,
2001). Only head-to-head comparisons of vaccine vectors can
reveal their relative effectiveness, and some such comparisons
have been reported in the last few years (for examples, see
363C. Cecil et al. / Virology 362 (2007) 362–373Casimiro et al., 2003; Doria-Rose et al., 2003; Shiver et al.,
2002).
The molecular form of the immunogen is another important
factor in the ultimate success of a vaccine vector. The optimal
configuration of a vaccine vector will require matching the
specific vector biology with the most immunogenic form of the
vectored protein. For example, studies of immunogen design
have been performed in the context of DNA and canarypox
vaccine vectors expressing SIV or HIV-1 group-specific
antigen (Gag) protein with widely varying results. In the
case of DNA, abrogation of Gag-directed budding increased
the cellular immune response in some cases (Bu et al., 2003;
Young and Ross, 2006), but not in another (Qiu et al., 2000),
while the canarypox vector expressing budding competent Gag
was the most immunogenic (Chen et al., 2005). This suggests
that the distinct biology and specific design of these genetic
vaccines resulted in the determination of different optimal
forms of Gag. It is in this context that defective Venezuelan
equine encephalitis virus replicon particle vectors (VRP) ex-
pressing various forms of SIV Gag were compared both with
respect to the properties of the expressed proteins in cell
culture and the strength and persistence of the cellular res-
ponses induced in mice.
Several groups have demonstrated the importance of a
cellular immune response in the natural control of both HIV-1
and SIV replication (Borrow et al., 1994; Brander and Walker,
1999; Davis et al., 2002; Edwards et al., 2002; Koup et al.,
1994; Letvin et al., 2006; Ogg et al., 1998; Picker, 2000;
Schmitz et al., 1999). For this reason, the Gag proteins of HIV-1
and SIVare key targets in vaccine studies. They are expressed at
a relatively high level by the virus, are fairly conserved and
carry a high density of CTL epitopes (Bertoletti et al., 1998;
Johnson et al., 1991; Johnson and Walker, 1994; Nixon et al.,
1988; Riviere et al., 1989).
Two lines of evidence form the basis for the use of the full-
length unmutated gag gene in the majority of vaccine vectors.
First, particulate antigens have been shown to be more
immunogenic than soluble proteins, possibly reflecting a
structure-related adjuvant effect (Michel et al., 1990; Paliard
et al., 2000). Second, full-length myristylated Gag (Gagmyr+)
expressed in the absence of any other viral proteins is able to
self-assemble into immature virus-like particles (Delchambre et
al., 1989; Gheysen et al., 1989; Wagner et al., 1992). It would be
expected that cytoplasmic Gagmyr+ would be processed for
presentation on MHC class I molecules and Gag-containing
VLPs would be taken up by dendritic cells for processing
through both the MHC class I and class II pathways (Yewdell et
al., 1999), thereby giving the maximum immune response.
However, the Gag protein can be produced in the cell in any of
several forms, which may influence the efficiency of antigen
presentation. Bu et al. (2003) demonstrated that assembly and
budding of the Gag immunogen are disrupted by mutating the
major homology region involved in multimerization or by
inserting a protein destruction signal. An alternative method for
blocking Gag release is to mutate the glycine at codon 2 that is
part of the signal for the co-translational modification of Gag
with the fatty acid myristic acid. Gag protein that lacks themyristic acid moiety (Gagmyr−) cannot target to the cell
membrane and is retained in the cytoplasm (Bryant and Ratner,
1990; Gottlinger et al., 1989; Qiu et al., 2000; Rein et al., 1986).
This cytoplasmic form of Gag is the immunogen that has been
used in the first clinical trial of a VRP vaccine, and preliminary,
still blinded results have been published (Chulay et al., 2006).
Gagmyr+ and Gagmyr− represent two forms of the Gag protein
that could be processed through the MHC class I pathway to
induce CD8+ T-cell responses. Gag protein also has been
expressed as a secreted unassembled protein by addition of the
t-PA signal sequence to its N-terminus (Qiu et al., 2000). An
alternative form of Gag, comprised of only the matrix and
capsid (MA/CA) coding domain, has been shown previously to
induce both humoral and cellular immune responses, either
delivered by viral vectors without the myristylation signal
(Caley et al., 1997; Davis et al., 2000) or by DNA vectors with
the myristylation signal (Bråve et al., 2005).
Gagmyr+ expressed in the context of the HIV genome
assembles and forms extracellular, enveloped particles in
cultured primate cell lines. However, in mouse cells that have
been engineered to allow HIVentry and gene expression, HIV-1
Gagmyr+ fails to localize to the plasma membrane or form virus
particles (Chen et al., 2001; Mariani et al., 2000). In a system
using an HIV-1/murine leukemia virus pseudotype to infect
murine cells expressing human cyclin T1, assembly of infectious
HIV-1 particles was demonstrated (Lund et al., 2004). In work
with virus vectors or DNA (Chen et al., 2005; Young and Ross,
2006) and experiments presented here, Gagmyr+ expressed alone
from a heterologous delivery system can also overcome the
block to assembly and efficiently produce extracellular Gag-
containing particles in murine cells.
In this study we utilized the VRP vector system (Davis et al.,
2002; Pushko et al., 1997) to produce phenotypically distinct
forms of the SIVsm H-4i Gag protein in both primary and
transformed murine cell lines, as well as in a primate cell line.
We found that three forms of the Gag immunogen (Gagmyr+,
Gagmyr− and MA/CA) were expressed to similar intracellular
levels in these cell lines. However, each form of Gag gave rise
to a distinct molecular structure that was consistently seen in all
three cell types, including the budding of virus-like particles
directed by expressed Gagmyr+. The effect of these structural
differences on immunogenicity was tested in VRP-immunized
BALB/c mice.
Results
Expression of different forms of SIV Gag in VRP-infected
monkey and murine cells
Fig. 1 describes the different forms of the SIVsm H-4i Gag
protein used in this study: (i) full-length myristylated Gag
(Gagmyr+), (ii) full-length non-myristylated Gag (Gagmyr−) and
(iii) a non-myristylated fragment spanning the matrix and
capsid domains (MA/CA). These were expressed from
individual VEE replicon vectors and packaged into VEE
replicon particles (VRP). The ablation of the myristylation
site is predicted to prevent the association of Gag or MA/CA
Table 1
Intracellular protein production (semi-quantitative Western blot)
Cell
line
Protein
Gagmyr+ Gagmyr− MA/CA
Exp. 1 Exp. 2 Exp. 1 Exp. 2 Exp. 1 Exp. 2
Vero 10,740 11,238 6578 9231 6992 8773
MEF 10,266 14,423 6213 10,753 7856 8767
Fig. 1. Diagram of three forms of the SIV Gag protein expressed from the VEE
replicon expression vector. The approximate locations of the M, membrane
targeting domain, MHR, major homology region, I, interaction domain, L, late
domains and x, mutant myristylation site are shown.
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et al., 1989; Rein et al., 1986). The truncation of the polyprotein
at the C-terminus of CA is expected to negatively affect RNA
binding and Gag–Gag interactions due to deletion of the
interaction (I) domain in NC (Bowzard et al., 1998; Dupraz and
Spahr, 1992; Jowett et al., 1992), as well as interactions with
cellular components involved in budding, ubiquitylation and
endosomal sorting due to deletion of the late (L) domain in p6
(reviewed in Morita and Sundquist, 2004).
The VRP were used to infect three different cell lines, Vero
cells (a monkey kidney fibroblast cell line), L929 cells (a mouse
fibroblast cell line) and primary murine embryonic fibroblasts
(MEFs) from outbred CD-1 mouse embryos, to determine
whether VRP-driven expression of different forms of SIV Gag
was altered in murine cells. Expression was assayed by SDS–
polyacrylamide gel electrophoresis (SDS–PAGE) and Western
blot (Fig. 2). Proteins with the expected apparent molecular
weights were detected in each lysate: myristylated or non-
myristylated Gag (55 kDa) or MA/CA (41 kDa). The faster
migrating bands in the Gagmyr+ and Gagmyr− lanes likely
represent products from a predicted internal initiation site near
the MA/CA boundary (Nicholson et al., 2006).
The analysis of intracellular protein production in monkey
and mouse cells was extended using the same assay, SDS–
PAGE and Western blot, in a semi-quantitative comparison
(Materials and methods). The results of two experiments (Table
1) show that VRP-infected Vero cells and MEFs contain
comparable amounts of each of the three forms of Gag.Fig. 2. Cell-associated Gag protein in VRP-infected cultured cells. Vero cells
(lanes 1–4), L929 cells (lanes 5–8) and MEFs (lanes 9–12) were infected at a
multiplicity of infection of 10 with VRP expressing either MA/CA (lanes 2, 6,
10), Gagmyr− (lanes 3, 7, 11) or Gagmyr+ (lanes 4, 8, 12) or mock-infected (lanes
1, 5, 9). At 18 h post-infection monolayers were lysed with NP-40 and the lysate
analyzed by SDS–PAGE on a 4–12% gradient polyacrylamide gel followed by
Western blot with an anti-capsid monoclonal antibody.The comparison of protein levels for a given form of Gag
across cell types using the semi-quantitative Western blot
protocol accurately reflects the relative levels of protein pro-
duction in the primate and murine cells examined. However,
when different forms of Gag are compared for a single cell type,
this protocol necessarily gives only an estimate because of
possible differences in accessibility of the capsid epitope to its
cognate monoclonal antibody. For example, it appears that
Gagmyr+ is produced in greater amounts than Gagmyr− or MA/
CA in both cell types, even when, as in this analysis, the
extracellular, budded Gagmyr+ is not included. It may be that
Gagmyr+, when bound to a nylon membrane, more efficiently
displays the capsid epitope or is actually present in higher
amounts due to greater stability in the cytoplasm of the VRP-
infected cell.
Each of the three forms of Gag protein expressed from VRP
was evaluated for its ability to direct budding of virus-like
particles from monkey and mouse cell lines. As a first step,
putative viral particles in the culture supernatants were partially
purified and concentrated by pelleting through a 20% sucrose
cushion. Proteins in the pellet were resuspended in PBS and
examined by SDS–PAGE and Western blot analysis. A protein
of the correct apparent molecular weight (55 kDa) was detected
in culture supernatants after expression of Gagmyr+ in all three
cell lines, but no supernatant viral proteins were seen after
expression of Gagmyr− or MA/CA in any of the three cell lines
(Fig. 3; myristylation-minus results shown only for Vero cells).
In an alternative assay for particle production, a commercial
ELISA (Zeptometrix) was used to measure the amount of
p55 Gag in high speed pellets of VRP-infected cell cultureFig. 3. Extracellular Gag protein in cultures of VRP-infected cells. Vero cells
(lanes 1–4), L929 cells (lane 5) and MEFs (lane 6) were infected as described
for Fig. 2 with VRP expressing either: MA/CA (lane 2), Gagmyr−(lane 3) and
Gagmyr+ (lanes 4–6). Cell supernatants were collected at 18 h post-infection,
layered over a 20% sucrose cushion and centrifuged. Pellets were resuspended
in PBS, dissociated with SDS and β-mercaptoethanol and analyzed by SDS–
PAGE and Western blot as described for Fig. 1.
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protease expression, any particles produced would be immature,
containing the p55 precursor polyprotein. Using this assay, it
was determined that Vero cells produced 0.17 pg of p55 per cell
and MEFs produced 0.75 pg of p55 per cell. More p55 also was
observed in culture supernatants of Gagmyr+-VRP-infected
MEF cultures than Gagmyr+-VRP-infected Vero cells when
assayed by Western blot (Fig. 3). The reason for higher level
p55-containing particle production from the MEFs is not
known, but taken together, these results demonstrate that VRP-
Gagmyr+-infected primary mouse cells are fully capable of
producing extracellular Gag-containing particles.
Characterization of different forms of Gag protein by
thin-section transmission electron microscopy
To further evaluate the intracellular localization and
morphology of each of the Gag proteins expressed from the
VRP, we examined both cell monolayers and pelleted super-
natants from each of the three cell lines by transmission electron
microscopy (TEM). Particles corresponding to the size of an
immature SIV virion were detected by TEM of negatively
stained pelleted culture supernatants from cells infected with
VRP expressing myristylated Gag but not Gagmyr− or MA/CA
(data not shown). Thin-section TEM of cell monolayers showed
budding particles at the surface of all three cell lines only when
Gagmyr+ was expressed from the VRP (Figs. 4A–C). Occa-
sionally, Gagmyr+ particles could be observed budding into
internal membranes (data not shown). Expression of Gagmyr−
unexpectedly produced stacked aggregates of Gag protein in the
cytoplasm (Figs. 4D–F) that were not detected in any of the cell
lines infected with either Gagmyr+-VRP or MA/CA-VRP, or in
mock-infected cells. Expression of the MA/CA form of GagFig. 4. Thin-section electron microscopy of VRP-infected cultured cells. Vero cells (
Gagmyr+-VRP (A–C) or Gagmyr− VRP (D–F). At 18 h post-infection monolayers wer
methods. Representative fields are shown for each culture at the same magnificationresulted in no discernable intracellular structures (MA/CA and
mock not shown).
The identity of the budding particles and the intracellular
aggregates was confirmed by immunogold labeling using an
SIV Matrix-specific monoclonal antibody followed by TEM.
Both the budding particles and the intracellular aggregates were
efficiently labeled with the colloidal gold-conjugated anti-
mouse IgG secondary antibody, indicating that these two forms
did contain Gag protein (Figs. 5A–C). These TEM results
confirmed the Western blot and p27 ELISA results showing
Gag-containing particle production by Gagmyr+-VRP-infected
monkey and mouse cells and revealed that high level expression
from the VEE replicon vector of Gagmyr−, a form of Gag that
cannot associate normally with the plasma membrane, but
retains the I and L domains, leads to intracellular accumulation
of distinctive aggregates. The formation of such distinct Gag-
containing structures in VRP-infected murine cells suggested
that changes in myristylation and aggregation might signifi-
cantly affect the immunogenicity of Gag in the VRP-immunized
BALB/c mouse.
Identification of SIV Gag H-2d-restricted peptides
The ELISPOT assay for Gag-specific cellular immunity is a
straightforward, quantitative method for comparing the immuno-
genicity of two vaccines. To establish this assay for different
forms of Gag expressed by VRP in the BALB/c mouse, we tested
a library of 125 peptides representing the entire SIV Gag protein
and identified the most reactive peptides in an IFN-γ ELISPOT.
Peptides spanning the Gag protein of SIVmac 239 (15 mers
overlapping by 11) were obtained from the NIHAIDSRepository
and selectively mixed using an overlapping checkerboard
protocol. These mixtures were used in an ELISPOT assay toA, D), L929 cells (B, E) or MEFs (C, F) were infected as for Fig. 2 with either
e fixed, embedded, sectioned and stained for TEM as described in Materials and
.
Fig. 5. Immunogold labeling followed by thin-section electron microscopy of VRP-infected Vero cells. Cells were infected as for Fig. 2 and fixed at 18 h post-infection.
Monolayers were sectioned, treated with anti-Matrix monoclonal antibody followed by colloidal gold-conjugated anti-mouse IgG antibody then stained with uranyl
acetate and lead citrate.
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from Gag-VRP vaccinated BALB/c mice (H-2d), and three
reactive peptides were identified (amino acid sequences in
Materials and methods). Stimulation with any one of these
peptides gave at least 70 spots per 1×106 cells after subtraction of
the average background seen with the irrelevant influenza HA
peptide and no peptide negative controls. All three reactive
peptides map to the MA/CA region of Gag. Results to be
described were obtained with a pool of all three positive peptides.
To determine whether this pool of peptides contains
determinants that are presented in the context of class I or
class II MHC antigens, or both, splenocytes were isolated from
eight MA/CA-VRP-immunized mice at 3 weeks post-boost,
stimulated with the pool of three reactive peptides and analyzed
by intracellular cytokine staining (ICS) for IFN-γ. Flow
cytometry was used to measure intracellular IFN-γ staining of
spleen cells that also had been stained for both CD4 and CD8
(data not shown). Both CD4+ and CD8+ T cells expressed
increased levels of intracellular IFN-γ following stimulation
with the peptide pool compared to cells incubated with control
peptides. Therefore, the pool of H-2d reactive peptides contains
both class I and class II determinants. This result is consistent
with the induction of a balanced cellular immune response by the
VRP vectors, including both CD8+ T cells and CD4+ T helper
cells, which support T and B cell expansion.
Immunogenicity of the various forms of Gag in BALB/c mice
Having demonstrated that VRP-expressed forms of Gag give
similar phenotypes in cultured monkey cells and in primary
mouse cells and that in both of these cell types the different
forms of Gag are distinguished by their morphology and ability
to form particles, groups of BALB/c mice were vaccinated with
each of the three VRP to test whether the phenotypes observed
in cell culture affect the immunogenicity of Gag.
In three separate experiments, groups of BALB/c mice were
each inoculated with a different form of Gag-VRP at week 0 and
boosted at week 4. At 5, 10 and 14 weeks (1, 6 and 10 weeks
post-boost) a subset of mice from each immunized group
was euthanized, and splenocytes were isolated and tested in an
IFN-γ ELISPOTassay using a mixture of the three Gag-reactive
peptides (Fig. 6). In Figs. 6A–C the number of IFN-γ-producing cells (spots) per 1×106 splenocytes for individual
mice harvested at each time point is represented as the percent
of the median number of spots detected at week 5 for each VRP
group. This representation illustrates the relative decrease in the
antigen-specific cellular response at later times post-boost for
the three VRP groups. A comparison of the difference between
the 100% level (equal to the median at week 5) and the median
percent at weeks 10 and 14 for each VRP group (shown by the
bars) shows that a higher number of Gag-specific IFN-γ-
producing cells are maintained in the MACA-VRP group than
in the Gagmyr+-VRP group at both later time points. The
decrease in median spot numbers during the time course from
the acute phase (5 weeks, set at 100%) to the memory phase (14
weeks) for each VRP group in the individual experiments is
shown in Figs. 6D–F.
Statistical comparisons of the number of IFN-γ-producing
cells per 1×106 splenocytes were made among the three VRP
groups at each time point, and between each VRP group at each
time point, combining values for all three experiments (Table 2).
This analysis showed a significant difference across all groups
at week 10 (median values of 211, 319 and 305, p=0.03) and at
week 14 (median values of 163, 182 and 242, p=0.006). When
the three experiments were examined in pairwise comparisons,
we observed a highly significant difference at week 14 between
Gagmyr+ and MA/CA both in terms of spots per 1×106
splenocytes (median values 163 and 242, p=0.0002; Table 2)
and percent of median spots per 1×106 cells at week 5 (median
values=0.377 and 0.670, p<0.0001; Fig. 6C). Taken together,
these results show that immunizations with VRP expressing
different forms of Gag give acute cellular immune responses in
BALB/c mice that are statistically equivalent, but that at later
times the response to MA/CA-VRP is maintained at a
significantly higher level than that to Gagmyr+-VRP, with a
50% greater median number of IFN-γ-secreting cells at week 14
in the combined experiments. Although the cellular responses to
all types of Gag-VRP decreased between 5 weeks and 14
weeks, as would be expected in a comparison of IFN-γ-
secreting cells in the acute and memory phases of the response,
in each case the decrease was less when MA/CA was the
immunogen.
The humoral immune responses induced by Gagmyr+-VRP,
Gagmyr−-VRP and MA/CA-VRP vaccination were compared
Fig. 6. ELISPOT assay of splenocytes from Gag-VRP-immunized BALB/c mice. Mice were immunized with Gagmyr+-, Gagmyr− or MA/CA-VRP at weeks 0 and 4.
Splenocytes were harvested from groups of mice at either week 5, 10 or 14 and stimulated with a pool of Gag-reactive peptides in an IFN-γ ELISPOTassay (Materials
and methods). A: IFN-γ-secreting cells (spots) per 1×106 cells in individual spleens for the three independent experiments combined plotted as a percent of the median
number of spots detected at 5 weeks (1 week post-boost). N=24 for Gagmyr+, N=24 for Gagmyr−, N=34 for MA/CA. B: Spots per 1×106 cells at 10 weeks (6 weeks
post-boost) plotted as a percent of the median number of spots detected at 5 weeks. Bars represent median percents for each group at 10 weeks. N=16 for all groups.
Experiment three did not include a 10 week time point. C: Spots per 1×106 cells at 14 weeks (10 weeks post-boost) plotted as a percent of the median number of spots
detected at 5 weeks. Bars represent median percents for each group at 14 weeks. N=24 for Gagmyr+, N=24 for Gagmyr−, N=31 for MA/CA. D–F: Median spots per
1×106 cells for each of three independent experiments represented as a percent of the median spots per 1×106 cells at week 5. Insets show the median spots per 1×106
cells at 5 weeks for each group in each experiment. Solid inverted triangles, MA/CA group; open circles, Gagmyr− group; solid circles, Gagmyr+ group.
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(Davis et al., 2000). Median titers at 10 weeks post-boost in the
three separate mouse immunization experiments described
above were 10,000, 20,000 and 7500 for Gagmyr+, 20,000,
60,000 and 10,000 for Gagmyr− and 10,000, 20,000 and 5000 for
MA/CA, respectively. Two-group comparisons showed that
Gagmyr− induced significantly more binding antibody than
Gagmyr+ in two of three experiments (p=0.002, 0.02 and 0.46),Table 2
Statistical Comparisons—IFN-γ ELISPOT experiments
Comparison across all three groups Tw
Median spots/106 cells p-value W
Week 5
Gagmyr+ 432 Ga
Gagmyr− 378 0.74 Ga
MA/CA 361 Ga
Week 10
Gagmyr+ 211
Gagmyr− 319 0.03
MA/CA 305
Week 14
Gagmyr+ 163 Ga
Gagmyr− 182 0.006 Ga
MA/CA 242 Gaand in one of three experiments induced more than MA/CA
(p=0.001, 0.10 and 0.12). ELISA titers induced by Gagmyr+ and
MA/CAwere not significantly different (p=0.99, 0.61 and 0.78).
Discussion
The goal of this study was to determine the expression,
morphologic and immunogenic phenotypes of three alternativeo-group comparisons
eek 5 Median spots per 1×106 cells p-value
gmyr+/Gagmyr− 432/378 0.80
gmyr+/MA/CA 432/361 0.66
gmyr−/MA/CA 378/361 0.92
gmyr+/Gagmyr− 163/182 0.16
gmyr+/MA/CA 163/242 0.0002
gmyr−/MA/CA 182/242 0.22
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model. The result would be considered when choosing
immunogens for ongoing primate studies in support of HIV-1
vaccine development for humans. These experiments also
represent an example of an empirical head-to-head test of
different forms of the same immunogen to determine the form
that takes best advantage of a specific vector biology.
Two developments paved the way for the use of VRP in the
BALB/c mouse in this study. First, using SIV Gag-VRP we
demonstrated that three distinct forms of SIVsm H-4i Gag show
similar in vitro phenotypes in both a primate cell line and
primary mouse fibroblasts. Second, reactive SIV MA/CA
peptides were identified in an IFN-γ ELISPOT assay for
BALB/c mice. These combined results indicated that Gag-VRP
vaccination of the BALB/c mouse would be a useful model in
which to compare different forms of SIV Gag for their ability to
induce a cellular immune response.
Although the very distinct molecular structures found in
cultured monkey and murine cells suggested that the three
forms of Gag might differ dramatically in immunogenicity, our
results revealed no significant difference in the humoral
responses or in the acute phase of the cellular response.
However, in IFN-γ ELISPOT assays, the average number of
Gag-reactive splenocytes was maintained at a 50% higher level
in the memory phase when MA/CA was the immunogen.
The incremental improvement in maintenance of antigen-
specific T cells, as opposed to any dramatic increase in the
initial cellular response, may reflect the identity of the VRP-
infected cell. Wild-type VEE and VRP packaged with wild-type
glycoproteins are found very soon after infection in dendritic
cells in the draining lymph node with the properties of antigen-
presenting cells. However, mutations in the glycoproteins, such
as those used in this study, direct the VRP to different cells in
the draining lymph node (MacDonald and Johnston, 2000; West
and Johnston, unpublished results), cells which may be
involved in cross-presentation rather than direct presentation
of antigens. In the context of a cross-presenting cell, the
different molecular structures of Gag immunogen tested here
may have only a small, but nonetheless significant, impact on
the immune response induced by VRP vaccination. The further
characterization of VRP target cells in the lymph node is
currently underway.
The nature of the cellular target was addressed in a
previous study of intramuscular DNA vaccination, in which
the expressed Gagmyr− immunogen gave lower CTL
responses than expression of either particle-forming Gagmyr+
or secreted, non-particle-forming Sc-Gag (Qiu et al., 2000).
One interpretation of this result is that transfer of protein
from transduced muscle cells to migratory dendritic cells
(cross-presentation) is more efficient with the secreted forms
of Gag.
At the outset of this study, we could not assume that different
forms of Gag would behave in the mouse model the same way
they behave in the more relevant primate background. There are
numerous steps in the HIV-1 replication cycle that appear to be
blocked in mouse cells (Atchison et al., 1996; Feng et al., 1996;
Landau et al., 1988). It has been observed that assembly at theplasma membrane of murine cells occurs at very inefficient
levels (Mariani et al., 2000). Using the VRP system, we were
able to induce particle budding in a primate cell line (Vero) and
in both transformed (L929) and primary (MEF) murine cells. It
is likely that the overexpression of Gag from the strong 26S
promoter of the VRP overcame the assembly block in the
murine cells and allowed Gagmyr+ to assemble and bud
(Hatziioannou et al., 2005). Infection of a murine myocyte
cell line, C2C12, with a canarypox vector expressing HIV Gag,
protease and Env also showed budding of virus-like particles
(Chen et al., 2005). It may be that expression levels in this
vector system also were sufficiently high to overcome the block
to assembly.
Unexpectedly, expression of Gagmyr− by the VRP vector
resulted in accumulation in the cytoplasm of distinctive Gag-
containing aggregates that often had the appearance of
concentric arcs associated with small electron dense particles.
It is possible that aggregation results from high level expression
of full-length mutated Gag that cannot associate with the plasma
membrane. Although purely speculative, it may be that the
specific morphology shown by the Gagmyr− aggregates repre-
sents an early stage in the development of an aggresome whose
maturation has been aborted due to VRP effects on cellular
biosynthesis (Kopito, 2000).
The canarypox vector expressing non-myristylated Gag did
not produce an intracellular aggregated form, perhaps because
the intracellular concentration was not high enough or because
protease was also expressed from that vector (Chen et al.,
2005). However, an aggregate with similar morphology was
detected in insect cells infected with a baculovirus vector
expressing SIV Gagmyr+-Pol (Yamshchikov et al., 1995). In this
case, the level of Gagmyr+ expression from the baculovirus
vector may have saturated the limited sites for budding and
raised the cytoplasmic concentration of Gag over the threshold
for aggregation.
In the context of the VRP vector, our results show that
delivery of MA/CA maintains a significantly greater number of
antigen-specific IFN-γ-secreting splenocytes during the mem-
ory phase compared to Gagmyr+, suggesting that among the
forms of Gag tested, MA/CA is the immunogen of choice for
this vaccine vector. The modest improvement in the longevity of
the response induced by this altered form of Gag may or may
not translate into other vaccine vector systems. However, it is
likely that the most effective HIV vaccine will combine several
such incremental improvements, and with that in mind, the MA/
CA form of Gag should be considered when testing vaccine
vectors for efficacy against HIV.
Materials and methods
Cells and plasmids
Vero and L929 cells were obtained from the American Type
Culture Collection and were maintained as recommended. BHK
cells were maintained and prepared for electroporation as
described previously (Davis et al., 2000; Liljeström and Garoff,
1991).
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used as the template for PCR to generate the gag genes that
were inserted into the pVR21 vector (Balasuriya et al., 2000).
Primers were designed to amplify from the 3′ end of the nsp4
gene of VEE through the 26S promoter and the 5′ leader of the
26S mRNA. Overlapping PCR was used to join this VEE
vector-derived fragment upstream of the following gag gene
segments: (i) the full-length gag gene encoding the intact
myristylation signal (encoding Gagmyr+), (ii) the full-length
gag gene with a change in codon 2 from Gly to Ala to ablate the
myristylation signal (encoding Gagmyr−) and (iii) the matrix-
capsid region of gag also containing the change in codon 2
(encoding MA/CA). The overlapping PCR products spanned
from either the AvrII site (nt 5952 from the VEE 5′ end) or the
SwaI site (nt 6962) in nsP4, through the 26S mRNA promoter
and the SIV gene to a unique PmeI site added at the 3′ end of
the SIV sequence. This PCR product was cloned into the PCR-
Blunt vector (Invitrogen) and validated by sequencing.
Flanking upstream AvrII or SwaI sites and the downstream
PmeI site were then used to subclone the 26S transcription units
with the SIV genes into the pVR21 vector. For the first two
mouse immunization experiments, a non-myristylated MA/CA-
expressing pVR2 vector was used (Davis et al., 2000), which
differs from the MA/CA-expressing pVR21 vector described
above only in that a different cloning strategy for pVR2
necessarily omitted the downstream 14 nts of the 30-nt-long
26S mRNA 5′ leader. The MA/CA-expressing pVR21 vector
containing the full leader sequence was compared to the pVR2
vector with respect to level of MA/CA expression in MEFs and
induction of cellular immunity in the third mouse immunization
experiment. The two MA/CAvectors gave comparable levels of
expression in vitro and statistically equivalent numbers of
interferon (IFN)-γ-secreting cells in the ELISPOT assay at both
1 and 10 weeks post-boost. Therefore, the results for both of
these vectors were combined for statistical comparison to
Gagmyr− and Gagmyr+.
Each of the VEE Gag expression vectors was used in an in
vitro transcription reaction (mMessage mMachine, Ambion,
Inc.) to generate VEE replicon RNA. Capsid helper RNA and
V3014 glycoprotein helper RNA (encoding independently
attenuating mutations in the E1 and E2 glycoproteins; Grieder
et al., 1995) were transcribed in vitro from separate plasmids for
co-electroporation with the gag replicon RNA to produce VEE
replicon particles (VRP). VRP were partially purified, and the
infectious units (IU)/ml were determined for each preparation
on BHK cell monolayers as described previously (Davis et al.,
2000; Pushko et al., 1997).
Preparation of primary murine embryo fibroblasts (MEFs)
Pregnant CD-1 female mice (E13) were obtained from
Charles River Labs. Embryos were harvested at 15–16 days
gestation, rinsed in PBS and then transferred to complete
medium (Dulbecco's minimal essential medium with 10% FBS,
2 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomy-
cin and 10 mM HEPES). Tissue was minced with a sterile razor
then homogenized by passing through a 16G needle severaltimes. The homogenate was incubated with trypsin at 37 °C for
a total of 90 min, during which time additional trypsin was
added to the cells at 30-minute intervals. Cells were incubated
on ice for 10 min to allow large aggregates to settle out and then
the supernatant was centrifuged for 10 min at 1000×g at 4 °C.
The resulting pellet was resuspended in complete medium, and
the cells were plated, allowed to grow at 37 °C, 5% CO2 and
passed twice to select for adherent fibroblasts before trypsiniz-
ing and freezing in DMSO-containing freezing medium. Prior
to use, cells were thawed, plated and passed once.
Western blot analysis of cultured cell lysate and supernatants
Monolayers of each cell type were prepared and grown to
∼80% confluence. Parallel cultures were infected with each
VRP at a multiplicity of infection (MOI) of 10 (10 IU per cell)
and incubated at 37 °C for 16–18 h prior to harvest. Cell
supernatants were collected and centrifuged at 18,000×g for
5min to remove cell debris and nuclei. Supernatant Gag particles
were then partially purified and concentrated by pelleting
through a 20% sucrose cushion for 16–18 h at 13,000×g at 4 °C.
The cell monolayer was rinsed with PBS and lysed in a buffer
containing 0.05MTris (pH 7.5), 0.1MNaCl, 0.1% EDTA, 0.2%
NP40 and a protease inhibitor cocktail (Complete, Roche
Applied Science). The cell lysate was collected and centrifuged
at 18,000×g for 5 min to remove cell membrane fragments and
nuclei. Aliquots of the pelleted culture supernatants and the
clarified cell lysates were dissociated in 1% sodium dodecyl
sulfate (SDS) and 2.75 mM β-mercaptoethanol and their
constituent proteins were resolved on a NuPAGE 4–12% Bis–
Tris polyacrylamide gel (Invitrogen) and transferred to PVDF
membrane (Amersham). After blocking overnight in 5%
Amersham membrane blocking agent in Tris-buffered saline
solution with Tween-20 [TBST: 0.1 M Tris–HCl, pH 7.5, 0.9%
(w/v) NaCl, 0.1% (v/v) Tween-20], themembrane was incubated
with SIV capsid-specific monoclonal antibody KK64 (NIH
AIDS Repository Cat.# 2321, Kent et al., 1991) at a dilution of
1:1000 in blocking solution. As the epitope for this monoclonal
antibody is in SIV capsid, it would react with all forms of Gag
protein used in this study. The membrane was washed
thoroughly and incubated with an HRP-conjugated horse anti-
mouse IgG secondary antibody (Promega) at a 1:1000 dilution in
TBST. Antibody-binding bands were detected using enhanced
chemiluminescence (ECL-Amersham) and Kodak Biomax film.
A semi-quantitative Western blot was performed as follows.
Any cells that had been released into the culture supernatant
during the 18 h of infection were collected by centrifugation,
lysed and added to the lysate of attached cells. This was
necessary because of the greater number of floating cells in the
Gagmyr+ cultures than in the Gagmyr− and MA/CA cultures.
Furthermore, a series of preliminary Western blots was
performed to determine the amount of cell lysate and anti-
capsid (CA) monoclonal antibody KK64 needed to give an
excess of antibody over antigen, thereby detecting total antigen
in each lysate. For the final Western blot, an equal number of
lysed cell equivalents was applied to the gel for each cell line
infected with each VRP, and an amount of antibody known to be
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bands in the final blots were quantified using Image J software.
Transmission electron microscopy and immunogold labeling
Each of the three cell lines (Vero, L929 and MEF) was
infected with each of the VRP at an MOI of 10. Cell
supernatants were removed, and the cell monolayers were
fixed with 3% glutaraldehyde in 0.15 M sodium phosphate
buffer and post-fixed with potassium ferrocyanide-reduced
osmium tetroxide. Cells were embedded in situ in Polybed 812
epoxy resin and cut into ultrathin sections of 70 nm. Sections
were post-stained in uranyl acetate and lead citrate then
photographed using a LEO EM-910 transmission electron
microscope (LEO Electron Microscopy Inc. Thornwood, NY)
at 80 kV. All sections were cut parallel to the substrate.
For immunogold labeling of the Gag particles, cells were
fixed in 2% paraformaldehyde, 0.5% glutaraldehyde. Cells
were embedded in L.R. White resin, sectioned parallel to the
substrate at 80 nm, labeled using a 1:100 dilution of a
monoclonal antibody to SIV Matrix (KK59—NIH AIDS
Repository Cat.# 2320, Kent et al., 1991), followed by a 1:50
dilution of a goat anti-mouse IgG secondary antibody
conjugated to a 5 nm colloidal gold particle (Polysciences,
Inc., Warrington, PA Cat.# 22730). KK59 monoclonal
antibody, like KK64 described above, reacted with all forms
of Gag used in this study and gave better binding than KK64
under the fixation conditions required for electron microscopy.
Immunogold labeling was followed by staining in uranyl
acetate and lead citrate and sections were photographed as
above.
Quantitation of extracellular particle production by p27 ELISA
Pellets obtained by high speed centrifugation of culture
supernatants were resuspended in a total volume of 200 μl and
analyzed using a Retro-tek SIV p27 antigen ELISA kit
(Zeptometrix) according to the manufacturer's recommenda-
tions. Determination of protein amount was made by compar-
ison to an antigen standard curve using a p27 sample provided
by the manufacturer. Duplicate values were averaged, and an
average background value for mock-infected cells was
subtracted. Final values (pg/ml) were multiplied by total
volume and divided by the number of cells from which the
supernatant was collected to derive pg of p27 per cell.
VRP vaccination of BALB/c mice
Five-week-old BALB/c mice were obtained from Charles
River Labs and housed in accordance with NIH and institutional
guidelines. Eight mice per group per time point were each
vaccinated with VRP expressing either Gagmyr+, Gagmyr− or
MA/CA at a total dose of 1×106 IU in 20 μl split equally
between the rear footpads. Vaccinations were given at 0 and 4
weeks. Serum was collected 1 day prior to the priming dose,
1 day prior to the boost and during the harvesting of the spleen
at 1, 6 or 10 weeks post-boost.Identification of SIV Gag H-2d-restricted peptides
The SIVmac 239 Gag peptide library (AIDS Research and
Reference Reagent Program, Cat.# 6204) consists of 125 15-
mer peptides that overlap by 11 amino acids. Peptides were
pooled and arranged in an overlapping checkerboard as
previously described (Kern et al., 1999; Guido Ferrari, personal
communication). Each pool consisted of 11 consecutive
peptides and 12 overlapping peptides. The checkerboard was
constructed such that one peptide was present in each of two
otherwise independent pools. Using the intersection of these
pools, an individual reactive peptide was easily identified. The
peptide pools were used in an IFN-γ ELISPOT assay (see
below) at a final concentration of 2 μg/ml to stimulate
splenocytes isolated from immunized BALB/c mice. The
mice were given two doses of 1×106 IU of Gagmyr+-VRP at
0 and 4 weeks. An IFN-γ ELISPOT assay was performed 3
weeks post-boost. The initial ELISPOT assay identified several
candidate pools. The individual peptides that comprised these
pools were then tested in a second IFN-γ ELISPOT assay,
thereby identifying three reactive peptides: KQIVQRHLVVE-
TETGTT (Cat.# 5236), NIYRRWIQLGLQKCV (Cat.# 5276)
and YVDRFYKSLRAEQTD (Cat.# 5285). Stimulation of
splenocytes from mice immunized with VRP-Gagmyr+ with a
pool of these three peptides gave 104, 158 or 74 spots per 106
cells, respectively, compared to 14 spots per 106 cells with a
pool of three negative peptides (Cat.#'s 5211, 5233 and 5255).
Assay of cellular immune response by IFN-γ ELISPOT
Multiscreen 96-well filtration plates (Millipore MHABS4510)
were incubated overnight at 4 °C with 100 μl per well of a 5 μg/
ml solution of antibody to mouse IFN-γ (AN18 Mabtech) in
sodium bicarbonate buffer (pH 9.6), washed with PBS and
blocked with AIM V (Invitrogen), 5% FBS medium. After bloc-
king, plates were washed again prior to adding peptides at a final
concentration of 2 μg/ml in a volume of 50 μl of AIMVmedium.
Groups of vaccinated mice were euthanized according to
institutional guidelines at week 1, 6 or 10 post-boost. Spleens
were removed and disrupted with a syringe plunger. The single
cell suspensions were then washed twice in a 1:10 dilution in
PBS of Alsever's solution (8 g dextrose, 5.5 g citric acid, 4.2 g
sodium chloride in a final volume of 1 l, PBS/A). The red
blood cells were lysed by adding 1 ml of sterile water,
immediately followed by 9 ml of PBS/A. Cells were washed
twice again then resuspended in RPMI medium. Splenocytes
were overlaid onto a Lympholyte M cushion (Cedarlane) and
centrifuged for 30 min at 2500 rpm and 20 °C. The buffy coat
was removed, resuspended in PBS/A and washed twice. After
the last wash, cells were resuspended in AIM V medium
without added serum, counted and adjusted to 1×107 cells/ml
and 50 μl was plated into wells of anti-IFN-γ antibody coated
96 well plates containing either 50 μl of peptide(s) to be tested,
an irrelevant control influenza virus hemagglutinin (HA)
peptide (IYSTVASSL), or a no peptide control. Three 15-
mer SIV Gag peptides identified from the mapping IFN-γ
ELISPOT assays, Cat.# 5236, Cat.# 5276 and Cat.# 5285,
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plates were incubated undisturbed for 20–24 h at 37 °C and
5% CO2. Plates were washed with chilled distilled water,
incubated on ice for 10 min, washed 10 times with wash buffer
(PBS with 0.01% Tween-20) and then incubated with 100 μl
per well of 1 μg/ml of biotinylated antibody to mouse IFN-γ
(R4-64A2, Mabtech) in PBS containing 0.01% Tween-20, 1%
bovine serum albumin (BSA) for 16–18 h at 4 °C. After the
incubation, plates were washed ten times with wash buffer.
Streptavidin–alkaline phosphatase (Mabtech) was diluted
1:1000 in PBS/0.01% Tween-20/1% BSA, 100 μl was added
to each well and plates were incubated for 1–2 h at 25 °C.
Plates were washed 10 times and spots were developed with
100 μl of BCIP/NBT substrate (Promega) prepared according
to the manufacturer's instructions. Spots were counted using
an automated plate reader with ImmunoSpot software (Cellular
Technology Ltd.).
Three non-reactive SIV Gag peptides were used as negative
controls in addition to the irrelevant Kd HA peptide (IYST-
VASSL) and no peptide sample. Averaged negative HA and no
peptide control values for each spleen were subtracted from the
individual samples. Concanavalin A at a concentration of 5 μg/
ml was included in two wells of each splenocyte preparation as
a positive control for the presence of viable T cells.
ELISA for anti-MA/CA antibody
Antisera were tested for antibody against MA/CA as
described previously (Davis et al., 2000) except that six-His-
tagged MA/CA protein was made in Escherichia coli strain
BL21DE3 using the pET24a expression plasmid. Horseradish
peroxidase-linked anti-mouse IgG (Sigma) was used as the
secondary antibody. Titers represent the highest serum dilution
that gave an optical density at 450 nm of >0.2.
Statistical analysis of ELISPOT results
Nonparametric one-way analysis of variance (the Kruskal–
Wallis test using Van der Waerden normal scores) was used to
evaluate possible differences in ELISPOTand ELISA responses
across the Gagmyr+, Gagmyr− and MA/CA groups. The
Wilcoxon rank-sum test (using Van der Waerden normal
scores) was used for the two-group comparisons of Gagmyr+
to Gagmyr−, Gagmyr+ to MA/CA, and Gagmyr− to MA/CA.
Monte Carlo estimates of exact p-values were used. The
Bonferonni method was used to adjust p-values to account for
multiple comparisons. All of these statistical analyses were
performed using SAS statistical software, Version 9.1, SAS
Institute Inc., Cary, NC. The Mann–Whitney test was used to
compare values for the percent of median spots per 1×106 cells
at week 5 for the Gagmyr+-VRP and MA/CA-VRP groups at
week 14 (Instat program, GraphPad Software).
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